W
William W. Busse
Researcher at University of Wisconsin-Madison
Publications - 740
Citations - 62685
William W. Busse is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Asthma & Eosinophil. The author has an hindex of 115, co-authored 697 publications receiving 56703 citations. Previous affiliations of William W. Busse include National Institutes of Health & University at Buffalo.
Papers
More filters
Journal ArticleDOI
Fluticasone Propionate Reduces Oral Prednisone Use while It Improves Asthma Control and Quality of Life
Michael Noonan,Paul Chervinsky,William W. Busse,Steven C. Weisberg,Jacob L. Pinnas,P. De Boisblanc,Howard Boltansky,David S. Pearlman,Lawrence Repsher,Donald J Kellerman +9 more
TL;DR: Fluticasone propionate aerosol effectively and safely allowed most asthmatics dependent on oral corticosteroids to reduce or eliminate oral prednisone use while improving pulmonary function and quality of life.
Journal ArticleDOI
DNA methylation and childhood asthma in the inner city.
Ivana V. Yang,Brent S. Pedersen,Andrew H. Liu,George T. O'Connor,Stephen J. Teach,Meyer Kattan,Rana Tawil Misiak,Rebecca S. Gruchalla,Suzanne Steinbach,Stanley J. Szefler,Michelle A. Gill,Agustin Calatroni,Gloria David,Corinne E. Hennessy,Elizabeth J. Davidson,Weiming Zhang,Peter J. Gergen,Alkis Togias,William W. Busse,David A. Schwartz,David A. Schwartz +20 more
TL;DR: In this article, DNA methylation patterns and gene expression in inner-city children with persistent atopic asthma versus healthy control subjects were compared by using DNA and RNA from PBMCs.
Journal ArticleDOI
Omalizumab in Asthma: An Update on Recent Developments
Marc Humbert,William W. Busse,Nicola A. Hanania,Philip J. Lowe,Janice Canvin,Veit J. Erpenbeck,Stephen T. Holgate +6 more
TL;DR: Results from recent pooled data from randomized clinical trials and from a large prospective cohort study provide reassurance about the long-term safety of omalizumab.
Journal ArticleDOI
Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma
William W. Busse,Paul Chervinsky,John Condemi,William R. Lumry,Thomas L. Petty,Stephen I. Rennard,Robert G. Townley +6 more
TL;DR: Budesonide administered by Turbuhaler exhibited a dose response and was effective at low doses and demonstrated significant reduction in asthma symptoms and bronchodilator use compared with placebo.
Journal ArticleDOI
Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study
Thomas B. Casale,Allan T. Luskin,William W. Busse,Robert S. Zeiger,Benjamin Trzaskoma,Ming Yang,Noelle M. Griffin,Bradley E. Chipps +7 more
TL;DR: Omalizumab initiation in patients with asthma resulted in improved exacerbation rates, reduced hospitalizations, and improved ACT scores compared with pretreatment values, regardless of biomarker status.